Navigation Links
Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
Date:10/4/2011

INDIANAPOLIS, Oct. 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it is improving its environmental footprint by achieving two of the company's three environmental goals ahead of schedule. Through the end of 2010, the company reduced the amount of waste sent to landfills by about 50 percent and has reduced its water intake by more than 30 percent. Lilly remains on track to meet its energy goal. Lilly has improved the energy efficiency of its operations by almost 12 percent while greenhouse gas emissions have been reduced by more than 9 percent through 2010.  

The goals were established for a five-year period beginning in 2008, using 2007 performance as a baseline. The company had aimed for a 40 percent reduction in waste to landfills and a 25 percent reduction in water intake by 2013. By 2013, the company hopes to achieve a 15 percent improvement in energy efficiency and in reducing greenhouse gas emissions.

"Through the efforts of our employees worldwide, we're making great progress to lessen our environmental impact in the communities where we operate," said Steve Gillman, vice president of health, safety, and environment. "We take this responsibility seriously and remain committed to finding more ways to use resources more efficiently and improve our performance."

Lilly has been able to avoid disposing of waste by reducing, reusing, and recycling in its business operations. Such efforts have resulted in only 10 percent of waste being sent to landfills last year. The company has six locations that have achieved a zero-landfill status including facilities in research, manufacturing and distribution.

Overall in 2010, the company reused approximately 65 percent of its waste. For example, mycelia, a solid material left after a fermentation process, is being used as a soil conditioner on farmland to improve plant
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... metabolism of stromal support cells and immune cells ... types in the development of diseases could open ... That was the conclusion of a review article by ... journal Nature . , Prof. Peter Carmeliet: "Consider ... metabolism of cancer cells has been examined in minute ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... conference organized in London by the Breast Cancer Campaign charity ... killer disease. //Instead it may become a long-term manageable disorder ... breast cancer patients has increased due to the significant developments ... revealed at the conference that the recurrence of the cancer ...
... with medical consultations and patients are seen tapping the ... medial ailments, especially ones they would like to hide ... infections scored very high on the search list and ... share of attention.NHS direct, the helpline is known to ...
... treatment was potentially beneficial in slowing and preventing ... (AMD). A recent study, the Complications of Age-Related ... from the National Eye Institute (NEI) of the ... laser treatment is ineffective in preventing complications of ...
... A recent research has found that more stress can lead ... restrain the cancer. //, ,A remarkable finding suggests that ... growth of cancer. Norepinephrine, a hormone released during stress stimulates ... tissue around tumor cells. This enables the cells to move ...
... a drug commonly prescribed to treat seizures and migraine ... stones//, researchers at UT Southwestern Medical Center have found. ... how the long-term use of topiramate affects kidney-stone formation ... Journal of Kidney Diseases. ,Several case reports ...
... major depression can become symptom-free if they are willing ... to determine which work best for them, which may ... the mix. ,The largest study on treatments for ... 67 percent of patients achieved a full remission of ...
Cached Medicine News:Health News:Breast Cancer may no longer be a killer disease 2Health News:People with early AMD not benefited by Laser Treatment 2Health News:More Stress, More Cancer 2Health News:More Stress, More Cancer 3Health News:Drug Prescribed for Migraines and Seizures Increases Risk of Kidney Stones 2Health News:Drug Prescribed for Migraines and Seizures Increases Risk of Kidney Stones 3Health News:Carefully Monitored Treatment Can Help Those Who Suffer from Depression 2Health News:Carefully Monitored Treatment Can Help Those Who Suffer from Depression 3
Sabre 180, 230V, 50Hz is a powerful niche generator....
High performance capabilities in a multipurpose generator, blended cut modes, simultaneous independent coagulation, low voltage coagulation, valleylab REM safety substantially reduces the risk of pat...
Lorgnette pinhole occluder...
Black multi-pinhole occluder...
Medicine Products: